Moderation of Prazosin's Efficacy by Alcohol Withdrawal Symptoms.

The American Journal of Psychiatry
Rajita SinhaHelen C Fox

Abstract

Alcohol use disorder (AUD) is a leading cause of global disease burden. Chronic, heavy use increases the likelihood of alcohol withdrawal symptoms and associated secondary outcomes of alcohol craving and mood, anxiety, and sleep disturbances, which are predictive of poor treatment outcomes. The authors examined whether alcohol withdrawal symptoms moderate the efficacy of prazosin in reducing alcohol intake and associated secondary outcomes. A 12-week, double-blind, randomized, controlled proof-of-concept trial of prazosin (16 mg/day, with a 2-week titration) was conducted in community-recruited adults with current alcohol dependence (N=100) with varying levels of alcohol withdrawal symptoms assessed at treatment entry. Primary outcomes were daily self-reported drinking days and heavy drinking days, and secondary outcomes were average drinks/day and mood, anxiety, craving, and sleep quality ratings. Modified intent-to-treat analyses indicated a significant interaction of alcohol withdrawal symptom score by treatment by full-dose treatment period (weeks 3-12) for drinking days, heavy drinking days, and average drinks/day. By week 12, participants with high alcohol withdrawal symptoms on prazosin reported 7.07% heavy drinking days...Continue Reading

Associated Clinical Trials

References

Apr 7, 2005·JAMA : the Journal of the American Medical Association·James C GarbuttUNKNOWN Vivitrex Study Group
Oct 24, 2008·Alcoholism, Clinical and Experimental Research·Tracy L SimpsonMurray Raskind
Nov 27, 2008·Alcoholism, Clinical and Experimental Research·Dennis D RasmussenJanice C Froehlich
Jul 28, 2011·Current Psychiatry Reports·Rajita Sinha
Sep 17, 2011·Alcoholism, Clinical and Experimental Research·Helen C FoxRajita Sinha
Nov 6, 2013·JAMA Internal Medicine·Barbara J MasonAdnan Begovic
Nov 27, 2014·The New England Journal of Medicine·Marc A Schuckit
Apr 4, 2015·Alcoholism, Clinical and Experimental Research·Raye Z LittenGeorge F Koob
May 16, 2015·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·John R MantschYavin Shaham
Sep 26, 2015·Nature Neuroscience·Amy F T Arnsten
Dec 20, 2015·Alcoholism, Clinical and Experimental Research·Ismene L PetrakisElizabeth Ralevski
Jul 20, 2016·Proceedings of the National Academy of Sciences of the United States of America·Rajita SinhaDongju Seo
Aug 1, 2016·The Lancet. Psychiatry·George F Koob, Nora D Volkow
Feb 6, 2018·Trends in Molecular Medicine·Verica Milivojevic, Rajita Sinha
Apr 18, 2018·Journal of Addiction Medicine·Claire E WilcoxTracy Simpson
Aug 30, 2018·The American Journal of Psychiatry·Tracy L SimpsonMurray Raskind
Dec 7, 2018·The American Journal of Psychiatry·Rajita Sinha
Feb 2, 2019·The American Journal of Psychiatry·Robert Andrew Kleinman, Michael J Ostacher
May 26, 2020·Alcoholism, Clinical and Experimental Research·Verica MilivojevicHelen C Fox

❮ Previous
Next ❯

Citations

May 13, 2021·The American Journal of Psychiatry·Ned H Kalin
May 13, 2021·The American Journal of Psychiatry·Barbara J Mason
Jun 26, 2021·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Thatiane De Oliveira SergioFrederic W Hopf

❮ Previous
Next ❯

Software Mentioned

Ar
RStudio
SAS
MetricWire
CIWA

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.